Industry News

Join WhatsApp Channel 

Regulatory Affairs Courses

  • Roche presented positive results from the Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line (initial) treatment of people with previously untreated locally advanced or metastatic urothelial carcinoma (mUC) eligible and ineligible for cisplatin chemotherapy. In the study, Tecentriq plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) compared with platinum-based chemotherapy alone (median PFS=8.2 versus 6.3 months; hazard ratio (HR)=0.82, 95% CI: 0.70-0.96; p=0.007).

  • Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity while testing the below finished product batches manufactured utilizing active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited using the old Route of Synthesis.

  • Glenmark Pharmaceuticals Ltd., a research-led, integrated global pharmaceutical company, today announced that it has received approval from the Ministry of Healthcare, Russia to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film-coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age. Montlezir is expected to be available in the Russian market in Q3 FY 2019-20.

  • Caption: L-R: Mr. Vivek Seigell, Principal Director, PHD Chamber, Mr. BhargavKotadia, Managing Director, Sahajanand Medical Technologies, Shri. D. V. SadanandaGowda,Hon’ble Minister of Chemicals & Fertilizers, Govt. of India, Dr. D. K. Aggarwal, Sr. Vice President, PHD Chamber, Dr. T. S. Kler, Chairman (Hospitals), Health Committee, PHD Chamber, Prof. Bejon Misra, Chairman, Public Health Committee, PHD Chamber and Dr Jitendar Sharma, Industry Expert- Medical Technologies

  • Indoco Remedies announced that the Inspection Action Group (IAG) of the United Kingdom has confirmed that the GMP status for its Goa Plant I has been fully re-instated by UK regulator, The Medicines and Healthcare Products Regulatory Agency of the United Kingdom (UK-MHRA). This is an outcome of the full GMP inspection conducted by the MHRAfrom May 21 - 23, 2019.

  • Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China. 

    Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China.

  • EMA has recommended new measures to prevent serious and potentially fatal errors with the dosing of methotrexate for treating inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn’s disease. The recommendations result from a review of reports that patients are using methotrexate incorrectly despite previous measures to prevent errors.

Subscribe to Industry News